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. Therefore, early detection and monitoring of PN is important since dose modifications might prevent occurrence of severe PN and symptoms reverse in >50% of patients 13 . The treatment protocol of the GMMG MM5 trial included dose modification guidelines for BiPN based on previously published data (see supplemental material) and about 50% of patients in both arms showed improvement of PN during follow-up 5 . Loss of efficacy due to reduced cumulative doses is a major concern with treatment modifications. As published earlier, patients in the GMMG MM5 trial showed high treatment adherence and median cumulative bortezomib doses were higher in SC treated patients from both arms (VCD: SC 28.8 mg/ IV 27.9 mg; PAd: SC 28.9 mg/ IV 27.6 mg) 5 . . The majority of patients were treated with weekly instead of twice weekly bortezomib in the respective study 15 which underlines that not only route of administration but also dose intensity influences development of PN. Although the route of administration might be less important for the occurrence of BiPN in newly diagnosed patients receiving short-term treatment, we still recommend SC application, since other non PN AEs occur less frequently 5 .
Taken together, we confirm that pre-existing PN is the most important risk factor for BiPN even in the era of SC bortezomib. Therefore, physicians need to be aware of PN symptoms and dose modification guidelines. Occurrence of PN during therapy has no negative impact on treatment response.
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